Cost-Effectiveness of Aprepitant in Egyptian Patients Receiving Highly Emetogenic Therapy from the Third Party Payer Perspective

Saved in:
Bibliographic Details
Published in:Value in health 2014-11, Vol.17 (7), p.A634-A634
Main Authors: Helal, M, Elsisi, G
Format: Article
Language:English
Subjects:
Internal Medicine
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page A634
container_issue 7
container_start_page A634
container_title Value in health
container_volume 17
creator Helal, M
Elsisi, G
description
doi_str_mv 10.1016/j.jval.2014.08.2272
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1790456511</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1098301514042028</els_id><sourcerecordid>1790456511</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2002-26d8cacf31a8c747ea477fc4638f5fb7c1d6e66c41421b8599530bf8512366e23</originalsourceid><addsrcrecordid>eNo9kU1r3DAQhk1padK0v6BQdOzFrr6tvRTCsmkKgYZ8nIVWO9qVa8uupF3wLT-9Mpv2IgnxvDPMM1X1meCGYCK_dU13Mn1DMeENVg2lLX1TXRJBec1bxt6WN16pmmEiLqoPKXUYY8moeF9dFBRTKsRl9bIeU643zoHN_gQBUkKjQ9dThMlnEzLyAW3285S9CejeZA8hJ_QAFvzJhz269ftDP6PNAHncQ_AWPR0gmmlGLo4DygcoHz7uSjbmuZwzRHQPMU3njh-rd870CT693lfV883maX1b3_368XN9fVdbijGtqdwpa6xjxCjb8hYMb1tnuWTKCbdtLdlJkNJywinZKrFaCYa3TglCmZRA2VX19Vx3iuOfI6SsB58s9L0JMB6TJu0KcyEFIQVlZ9TGMaUITk_RDybOmmC9qNedXtTrRb3GSi_qS-rLa4PjdoDd_8w_1wX4fgagjHnyELXtfRFm-t8wQ-rGYwzFgCY6UY3147K9ZXmEY15KKPYX7pmWlg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1790456511</pqid></control><display><type>article</type><title>Cost-Effectiveness of Aprepitant in Egyptian Patients Receiving Highly Emetogenic Therapy from the Third Party Payer Perspective</title><source>ScienceDirect Journals</source><creator>Helal, M ; Elsisi, G</creator><creatorcontrib>Helal, M ; Elsisi, G</creatorcontrib><identifier>ISSN: 1098-3015</identifier><identifier>EISSN: 1524-4733</identifier><identifier>DOI: 10.1016/j.jval.2014.08.2272</identifier><identifier>PMID: 27202255</identifier><language>eng</language><publisher>United States</publisher><subject>Internal Medicine</subject><ispartof>Value in health, 2014-11, Vol.17 (7), p.A634-A634</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27202255$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Helal, M</creatorcontrib><creatorcontrib>Elsisi, G</creatorcontrib><title>Cost-Effectiveness of Aprepitant in Egyptian Patients Receiving Highly Emetogenic Therapy from the Third Party Payer Perspective</title><title>Value in health</title><addtitle>Value Health</addtitle><subject>Internal Medicine</subject><issn>1098-3015</issn><issn>1524-4733</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNo9kU1r3DAQhk1padK0v6BQdOzFrr6tvRTCsmkKgYZ8nIVWO9qVa8uupF3wLT-9Mpv2IgnxvDPMM1X1meCGYCK_dU13Mn1DMeENVg2lLX1TXRJBec1bxt6WN16pmmEiLqoPKXUYY8moeF9dFBRTKsRl9bIeU643zoHN_gQBUkKjQ9dThMlnEzLyAW3285S9CejeZA8hJ_QAFvzJhz269ftDP6PNAHncQ_AWPR0gmmlGLo4DygcoHz7uSjbmuZwzRHQPMU3njh-rd870CT693lfV883maX1b3_368XN9fVdbijGtqdwpa6xjxCjb8hYMb1tnuWTKCbdtLdlJkNJywinZKrFaCYa3TglCmZRA2VX19Vx3iuOfI6SsB58s9L0JMB6TJu0KcyEFIQVlZ9TGMaUITk_RDybOmmC9qNedXtTrRb3GSi_qS-rLa4PjdoDd_8w_1wX4fgagjHnyELXtfRFm-t8wQ-rGYwzFgCY6UY3147K9ZXmEY15KKPYX7pmWlg</recordid><startdate>201411</startdate><enddate>201411</enddate><creator>Helal, M</creator><creator>Elsisi, G</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201411</creationdate><title>Cost-Effectiveness of Aprepitant in Egyptian Patients Receiving Highly Emetogenic Therapy from the Third Party Payer Perspective</title><author>Helal, M ; Elsisi, G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2002-26d8cacf31a8c747ea477fc4638f5fb7c1d6e66c41421b8599530bf8512366e23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Internal Medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Helal, M</creatorcontrib><creatorcontrib>Elsisi, G</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Value in health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Helal, M</au><au>Elsisi, G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost-Effectiveness of Aprepitant in Egyptian Patients Receiving Highly Emetogenic Therapy from the Third Party Payer Perspective</atitle><jtitle>Value in health</jtitle><addtitle>Value Health</addtitle><date>2014-11</date><risdate>2014</risdate><volume>17</volume><issue>7</issue><spage>A634</spage><epage>A634</epage><pages>A634-A634</pages><issn>1098-3015</issn><eissn>1524-4733</eissn><cop>United States</cop><pmid>27202255</pmid><doi>10.1016/j.jval.2014.08.2272</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1098-3015
ispartof Value in health, 2014-11, Vol.17 (7), p.A634-A634
issn 1098-3015
1524-4733
language eng
recordid cdi_proquest_miscellaneous_1790456511
source ScienceDirect Journals
subjects Internal Medicine
title Cost-Effectiveness of Aprepitant in Egyptian Patients Receiving Highly Emetogenic Therapy from the Third Party Payer Perspective
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T18%3A21%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost-Effectiveness%20of%20Aprepitant%20in%20Egyptian%20Patients%20Receiving%20Highly%20Emetogenic%20Therapy%20from%20the%20Third%20Party%20Payer%20Perspective&rft.jtitle=Value%20in%20health&rft.au=Helal,%20M&rft.date=2014-11&rft.volume=17&rft.issue=7&rft.spage=A634&rft.epage=A634&rft.pages=A634-A634&rft.issn=1098-3015&rft.eissn=1524-4733&rft_id=info:doi/10.1016/j.jval.2014.08.2272&rft_dat=%3Cproquest_cross%3E1790456511%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2002-26d8cacf31a8c747ea477fc4638f5fb7c1d6e66c41421b8599530bf8512366e23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1790456511&rft_id=info:pmid/27202255&rfr_iscdi=true